Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ), a rare debilitating central nervous system disease, were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ( ECTRIMS ), and have shown that Satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo in the overall population, representative of NMOSD patients ( hazard ratio [ HR ]=0.45, 95% Confidence Interval [ CI ]: 0.23-0.89; p=0.0184 ).
In the large ( approximately 67% ) subgroup of patients seropositive for AQP4-IgG antibodies, the effect was higher with a 74% reduction in risk of relapses ( HR=0.26, 95% CI: 0.11-0.63; p=0.0014 ).
People who are AQP4-IgG seropositive tend to experience a more severe disease course.
In the overall Satralizumab-treated population, 76.1% were relapse-free at 48 weeks, and 72.1% relapse-free at 96 weeks, compared to 61.9% and 51.2% with placebo, respectively.
Data from the AQP4-IgG seropositive subgroup have shown that 82.9% were relapse-free at 48 weeks and 76.5% relapse-free at 96 weeks when treated with Satralizumab, compared to 55.4% and 41.1% with placebo, respectively.
NMOSD is commonly associated with pathogenic antibodies ( AQP4-IgG ) that target and damage a specific cell type, called astrocytes, resulting in inflammatory lesions of the optic nerve(s), spinal cord and brain.
Through the use of a diagnostic biomarker test, most NMOSD patients are identified as AQP4-IgG seropositive; however, as many as one-third of patients with NMOSD are AQP4-IgG seronegative.
The condition is often misdiagnosed as multiple sclerosis.
Satralizumab inhibits IL-6 signaling, which is believed to play a key role in the inflammation that occurs in people with NMOSD, leading to damage and disability.
People with NMOSD experience unpredictable, severe relapses that directly cause cumulative, permanent neurological damage.
While first described 125 years ago, the underlying biology of NMOSD has only recently been understood.
The positive results from the pivotal SAkuraStar and SAkuraSky studies support the hypothesis that IL-6 plays a key role in this devastating disease that can take away people’s independence.
These SAkuraStar data add to the previously reported results for Satralizumab in combination with baseline therapy for people with NMOSD.
Initial phase III data for SAkuraSky were presented at the 34th ECTRIMS Congress in 2018. The data showed a 62% reduction in the risk of relapses in a representative population of both AQP4-IgG seropositive and AQP4-IgG seronegative patients in the overall study population ( HR=0.38, 95% CI: 0.16-0.88; p=0.0184 ) when used in combination with baseline therapy compared to placebo, and a 79% reduction in the risk of relapses in AQP4-IgG seropositive patients ( HR=0.21, 95% CI: 0.06-0.75; p=0.0086 ).
Overall, the proportion of patients with serious adverse events was similar between the Satralizumab monotherapy and placebo treatment groups in the SAkuraStar study; and between the Satralizumab added to baseline therapy and placebo added to baseline therapy treatment groups in the SAkuraSky study.
A lower rate of infections ( including serious infections ) was observed in patients treated with Satralizumab compared with the placebo group.
In both studies, most adverse events were mild to moderate, and the most common adverse events in the Satralizumab group were urinary tract infections and upper respiratory tract infections in the SAkuraStar study and upper respiratory tract infection, nasopharyngitis ( common cold ) and headache in the SAkuraSky study.
The data available across two controlled, randomized phase III clinical trials suggest that Satralizumab could be an efficacious option for a broad NMOSD patient population, whether given as a monotherapy or in combination with baseline therapy.
Satralizumab is administered every four weeks by subcutaneous injection, which may be a convenient option for patients and caregivers.
NMOSD is a rare, lifelong and debilitating autoimmune disease of the central nervous system that primarily damages the optic nerve(s) and spinal cord, causing blindness, muscle weakness and paralysis.
People with NMOSD experience unpredictable, severe relapses directly causing cumulative, permanent, neurological damage and disability. In some cases, relapse can result in death.
NMOSD affects over 10,000 people in Europe, 15,000 people in the United States and up to hundreds of thousands of people worldwide.
The disease is most common among non-Caucasian women in their 30s and 40s. ( Xagena )
Source: Genentech, 2019
FDA has approved Ponvory, an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio in reducing annual relapses and brain lesions
The U.S. Food and Drug Administration ( FDA ) has approved Ponvory ( Ponesimod ), a once-daily oral selective sphingosine-1-phosphate...
A small number of patients receiving Dimethyl fumarate ( Tecfidera ) for the treatment of multiple sclerosis have developed progressive...
Ponvory for the treatment of adults with relapsing forms of multiple sclerosis with active disease - Approved in European Union
The European Commission ( EC ) has approved Ponvory ( Ponesimod ) for the treatment of adult patients with relapsing...
Kesimpta, self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis, FDA approved
The FDA ( US Food and Drug Administration ) has approved Kesimpta ( Ofatumumab, formerly OMB157 ) as an injection...
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the...
Living near major roads or highways is linked to higher incidence of dementia, Parkinson's disease, Alzheimer's disease and multiple sclerosis,...
Mayzent for adult patients with secondary progressive multiple sclerosis with active disease, approved in European Union
The European Commission ( EC ) has approved Mayzent ( Siponimod ) for the treatment of adult patients with secondary...
Effect of baseline age on efficacy and safety of Siponimod in patients with active secondary progressive multiple sclerosis
Siponimod ( Mayzent ) is a selective sphingosine 1-phosphate receptor ( S1P1 and S1P5 ) modulator, approved in the USA...
Relapsing multiple sclerosis: Ofatumumab has demonstrated superiority versus Teriflunomide in ASCLEPIOS I and II
Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both...